Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03773302
Title	Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Recruitment	Terminated
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	QED Therapeutics, Inc.
Indications	cholangiocarcinoma
Therapies	Cisplatin + Gemcitabine Infigratinib
Age Groups:	adult \| senior
Covered Countries	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS